Chart-Typ:
Zeitraum:
| Neurocrine Announces Commercial Launch Of Crenessity In US | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal... ► Artikel lesen |
| Neurocrine's CRENESSITY Gains FDA Approval For Treating Congenital Adrenal Hyperplasia | WASHINGTON (dpa-AFX) - Neurocrine Biosciences, Inc. (NBIX) said that the U.S. Food and Drug Administration has approved CRENESSITY (crinecerfont) capsules and oral solution as an adjunctive... ► Artikel lesen |
| Neurocrine Biosciences, Inc.: Neurocrine Biosciences Announces FDA Approval of CRENESSITY (crinecerfont), a First-in-Class Treatment for Children and Adults With Classic Congenital Adrenal Hyperplasia | CRENESSITY, the first new treatment available in 70 years to the classic congenital adrenal hyperplasia (CAH) community, offers a paradigm-shifting treatment approach
FDA approval... ► Artikel lesen |
| Amgen Announces 2025 First Quarter Dividend | THOUSAND OAKS, Calif., Dec. 10, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that its Board of Directors declared a $2.38 per share dividend for... ► Artikel lesen |
| Amgen's Phase 3 Study: BLINCYTO Plus Chemotherapy Improves Survival In Pediatric B-ALL Patients | THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced new data from a Phase 3 study demonstrating that adding BLINCYTO (blinatumomab) to chemotherapy significantly improves disease-free survival... ► Artikel lesen |
| Amgen: Blincyto (blinatumomab) Added To Chemotherapy Significantly Improves Survival In Newly Diagnosed Pediatric Patients With B-cell Precursor Acute Lymphoblastic Leukemia (b-all) | Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96%
THOUSAND OAKS, Calif., Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced... ► Artikel lesen |
| Biogen Aktie: Skepsis wächst merklich | Die Aktie des US-Biotech-Unternehmens Biogen verzeichnet zum Ende des Jahres 2024 weitere Verluste. Der Kurs fiel am 14. Dezember auf 150,03 USD, was einem Tagesrückgang von 3,41 Prozent entspricht.... ► Artikel lesen |
| Biogen: "LEQEMBI" (Lecanemab) Approved for the Treatment of Early Alzheimer's Disease in Mexico | TOKYO and CAMBRIDGE, Mass., Dec 5, 2024 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that the Federal Commission forthe Protection Against Sanitary Risk (COFEPRIS) in Mexico has... ► Artikel lesen |
| Eisai And Biogen: Mexico Approves LEQEMBI For Early Alzheimer's Disease Treatment | WESTON (dpa-AFX) - Eisai Co., Ltd. (ESALF.PK) and Biogen Inc. (BIIB) announced that the Federal Commission for the Protection Against Sanitary Risk (COFEPRIS) in Mexico has approved humanized... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ESTRELLA IMMUNOPHARMA INC finden Sie auf Wallstreet Online.
